Atsushi Momobayashi

Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes

Yoshimasa Aso, Maiko Fukushima, Masaaki Sagara et al. · Diabetes Research and Clinical Practice · 2015 · 43 citations

Medicine, Endocrinology, Immunology +16

Relation between serum high molecular weight adiponectin and serum ferritin or prohepcidin in patients with type 2 diabetes

Yoshimasa Aso, Kohzo Takebayashi, Sadao Wakabayashi et al. · Diabetes Research and Clinical Practice · 2010 · 41 citations

Medicine, Endocrinology, Internal Medicine +14

Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves’ disease

Y. Inukai, Atsushi Momobayashi, Naoto Sugawara et al. · European Journal of Endocrinology · 2007 · 39 citations

Life Sciences, Endocrinology, Immunology +13

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+ cells in patients with type 2 diabetes

Yoshimasa Aso, Teruo Jojima, Toshie Iijima et al. · Endocrine · 2015 · 34 citations

Medicine, Pharmacology, Pharmacotherapy +12

Bezafibrate, a peroxisome proliferator–activated receptor α agonist, decreases circulating CD14+CD16+ monocytes in patients with type 2 diabetes

Tomoko Terasawa, Yoshimasa Aso, Kyoko Omori et al. · Translational research · 2014 · 19 citations

Medicine, Immunology, Pharmacology +15